Clinical Trial Update: A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies [Phase 2]

View source ↗

Summary

This clinical trial update reports results from a Phase 2 dose-escalation study evaluating safety, PK/PD, and clinical activity of the gamma-secretase inhibitor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Drugs mentioned

• GSK525762

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2021-05-19